title: Central administration of the somatostatin analog octreotide induces captopril-insensitive sleep responses.
abstract: The effects of intracerebroventricular injections of the long-lasting somatostatin analog octreotide (Oct) were studied on sleep and behavior in rats. Pyrogen-free physiological saline and Oct (0.001, 0.01, 0.1 microgram) or vehicle were administered at light onset, and the electroencephalogram (EEG), motor activity, and cortical brain temperature were recorded during the 12-h light period. Plasma growth hormone (GH) concentrations were measured in samples taken at 30-min intervals after Oct. Oct (0.01 and 0.1 microgram) suppressed non-rapid eye movement sleep (NREMS) for 1-2 h. NREMS intensity (delta EEG activity during NREMS) dose dependently increased in hour 3 postinjection and thereafter (0.1 microgram). Plasma GH concentrations were suppressed after Oct (0.01 and 0.1 microgram), but pulses of GH secretions occurred 90-120 min postinjection in each rat. Oct (0.1 microgram) enhanced behavioral activity, including prompt drinking followed by grooming, scratching, and feeding. Intracerebroventricular injection of the angiotensin-converting enzyme inhibitor captopril (30 microgram, 10 min before Oct), blocked these behavioral responses but not the Oct-induced sleep alterations. The changes in sleep after intracerebroventricular Oct suggest an intracerebral action site and might result from Oct-induced variations in the sleep-promoting activity of GH-releasing hormone.
authors.affiliation: Department of Physiology, A. Szent-Györgyi Medical University, 6720 Szeged, Hungary.
authors.forename: L
authors.initials: L
authors.lastname: Beranek
authors.forename: I
authors.initials: I
authors.lastname: Hajdu
authors.forename: J
authors.initials: J
authors.lastname: Gardi
authors.forename: P
authors.initials: P
authors.lastname: Taishi
authors.forename: F
authors.initials: F
authors.lastname: Obál
authors.forename: J M
authors.initials: JM
authors.lastname: Krueger
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D002216:Captopril / Q000494:pharmacology*; D004351:Drug Resistance; D019382:Human Growth Hormone / Q000097:blood; D007276:Injections, Intraventricular; D008297:Male; D015282:Octreotide / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012890:Sleep / Q000187:drug effects*; D012894:Sleep Stages / Q000187:drug effects; D013004:Somatostatin / Q000031:analogs & derivatives
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D019382:Human Growth Hormone; D013004:Somatostatin; D002216:Captopril; D015282:Octreotide